Asthma worsening after COVID-19 mRNA vaccination associated with younger age, atopy, and poor control
Background: Clinical factors linked to worsening after vaccination
In Japan’s 13-center REACTION study, 14.5% of patients with asthma and 0% of those with chronic obstructive pulmonary disease (COPD) reported worsening respiratory symptoms within one week after COVID-19 mRNA vaccination. Among patients with asthma, relatively younger age, atopic predisposition, lower fractional exhaled nitric oxide (FeNO), and poor asthma control were independently associated with worsening. However, this was a retrospective observational study and does not establish that vaccination caused the worsening.
Asthma and COPD can both involve sudden worsening of respiratory symptoms. Cases of asthma worsening after COVID-19 mRNA vaccination have been reported, but data directly comparing post-vaccination patterns of worsening and associated clinical factors in the two diseases have been limited. The researchers examined this question by analyzing medical records and patient surveys together.
Key findings: 56 of 387 patients with asthma reported worsening
The researchers enrolled 455 patients in Japan from September 2022 to September 2024. The asthma group included 387 patients, 30 of whom also had COPD; a separate COPD group comprised 68 patients. New or worsened shortness of breath, cough, wheezing, or sputum within one week after vaccination was assessed by questionnaire and defined as “vaccine-associated worsening.” Thus, 14.5% is the proportion of patients with asthma who reported this experience, not an incidence rate per vaccine dose.
In the asthma group, 56 patients reported worsening; none did so in the COPD group (P<0.001). The COPD sample was small, however. The upper bound of the exact 95% confidence interval for its worsening rate was 5.3%, so the observed zero cases cannot be interpreted as meaning there was no risk.
In a multivariable analysis adjusted for obesity and asthma severity, younger age, atopic predisposition, FeNO below 25 ppb, and poor asthma control were associated with worsening. Atopic predisposition was defined as having specific immunoglobulin E (IgE) at or above the threshold for at least one common inhaled allergen. For an Asthma Control Test (ACT) score below 20, the adjusted odds ratio was 5.46 (95% confidence interval 2.85–10.44). This is an odds comparison within the model; it does not represent an individual’s probability or absolute risk of worsening. In another model, a history of at least two exacerbations per year was also identified as an associated factor.
Most cases were mild, but 15 patients met the study’s definition of severe worsening. They had unscheduled medical visits; of these patients, 11 received systemic steroids and 4 were hospitalized. These healthcare-use categories overlap. The patients who received medical care improved quickly, and the researchers reported no serious outcomes.
Meaning and outlook: Focus on asthma control before vaccination rather than asserting causation
These findings add support for assessing asthma control before vaccination and reviewing recent exacerbation history. Low FeNO was also associated with worsening, but this does not mean that a low value itself is causal. The researchers discussed the possibility that treatments such as steroids lowered inflammatory markers; this mechanism was not confirmed by repeated measurements before and after vaccination.
Interpretation is also limited by recall bias from self-report, the lack of an unvaccinated control group, and residual confounding. Baseline characteristics such as age and atopic predisposition differed between the asthma and COPD groups, and the proportion of patients with severe asthma makes it difficult to apply the same worsening rate to all patients with asthma. The study also did not assess risk by vaccine product or dose number. Considering the overall benefits of vaccination, the researchers supported continuing vaccination while emphasizing asthma control before vaccination in higher-risk patients. However, this study did not directly test whether improving control prevents worsening after vaccination.
The study was published in the May 2026 issue of Allergy, Asthma & Immunology Research. Methods and results are available in the original paper.
Allergy, Published June 2026.
Summary: Bypassing the historical safety data deficits that frequently challenge vaccine confidence among individuals with obstructive airway diseases, this 13-institution multicenter historical cohort study maps the clinical trajectory of 455 enrolled patients. Utilizing high-depth multivariate logistic regression frameworks over comprehensive demographic, biomarer, and spirometric registries, the computational platform demonstrates that asthma patients experience a disproportionately higher rate of mRNA vaccine-associated exacerbations (14.5%) compared to the chronic obstructive pulmonary disease (COPD) cohort. The risk matrix isolates poorly controlled atopic asthma in younger individuals as the primary hyper-reactivity checkpoint. This profile delivers a precise, non-invasive computational baseline supporting continued vaccine translation while structurally prioritizing prior optimization of baseline asthma control within high-risk patient stratification channels.
During pre-vaccination visits for patients with asthma, these findings can inform a combined review of recent symptoms, ACT scores, annual exacerbation frequency, and atopic predisposition. For example, if a patient has poor recent symptom control and repeated exacerbations, the treating clinician could review current treatment and management and discuss a plan for seeking care if shortness of breath or wheezing worsens after vaccination. The study did not test the preventive effect of a specific management strategy or criteria for delaying vaccination. Nor does it conclude that people should avoid vaccination because they are young or have an atopic predisposition. The clinical focus is to maintain vaccination’s benefits while carefully assessing patients whose asthma is poorly controlled.